Varenicline and CV events: postmarketing experience in NZ

Author：  

Publisher： Adis International

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1383, 2012-01, pp. : 5-5

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Serious adverse CV events with varenicline

By  

Reactions Weekly, Vol. 1, Iss. 1360, 2011-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Psychiatric Adverse Events Associated with Varenicline: An Intensive Postmarketing Prospective Cohort Study in New Zealand

By Harrison-Woolrych Mira   Ashton Janelle  

Drug Safety, Vol. 34, Iss. 9, 2011-09 ,pp. : 763-772

Adis International

Access to resources Recommend Favorite

Cardiovascular Events in Patients taking Varenicline: A Case Series from Intensive Postmarketing Surveillance in New Zealand

By Harrison-Woolrych Mira  

Drug Safety, Vol. 35, Iss. 1, 2012-01 ,pp. : 33-43

Adis International

Access to resources Recommend Favorite

Analysis prompted by FDA shows varenicline's CV safety risk is low

By  

Reactions Weekly, Vol. 1, Iss. 1433, 2013-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

Link between varenicline and cardiovascular events questioned

By  

Reactions Weekly, Vol. 1, Iss. 1401, 2012-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite